Cargando…

Looking beyond 28-day all-cause mortality

A growing body of evidence indicates that survivors of intensive care have an impaired quality of life. It is not entirely clear from the available literature whether this impairment is a complication of critical illness or a complication of therapy. There is little evidence to guide physicians to t...

Descripción completa

Detalles Bibliográficos
Autor principal: Rubenfeld, Gordon
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137308/
https://www.ncbi.nlm.nih.gov/pubmed/12225601
_version_ 1782120428233293824
author Rubenfeld, Gordon
author_facet Rubenfeld, Gordon
author_sort Rubenfeld, Gordon
collection PubMed
description A growing body of evidence indicates that survivors of intensive care have an impaired quality of life. It is not entirely clear from the available literature whether this impairment is a complication of critical illness or a complication of therapy. There is little evidence to guide physicians to treatments in the intensive care unit that will minimize the effects of critical illness on these sequelae. Although the study by Rublee and colleagues in this issue of Critical Care provides little clinically useful information about the effects of antithrombin III on quality of life, it provides some insight into the challenges that investigators will encounter as we try to incorporate these outcomes into studies of critical illness.
format Text
id pubmed-137308
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1373082003-02-27 Looking beyond 28-day all-cause mortality Rubenfeld, Gordon Crit Care Commentary A growing body of evidence indicates that survivors of intensive care have an impaired quality of life. It is not entirely clear from the available literature whether this impairment is a complication of critical illness or a complication of therapy. There is little evidence to guide physicians to treatments in the intensive care unit that will minimize the effects of critical illness on these sequelae. Although the study by Rublee and colleagues in this issue of Critical Care provides little clinically useful information about the effects of antithrombin III on quality of life, it provides some insight into the challenges that investigators will encounter as we try to incorporate these outcomes into studies of critical illness. BioMed Central 2002 2002-07-08 /pmc/articles/PMC137308/ /pubmed/12225601 Text en Copyright © 2002 BioMed Central Ltd
spellingShingle Commentary
Rubenfeld, Gordon
Looking beyond 28-day all-cause mortality
title Looking beyond 28-day all-cause mortality
title_full Looking beyond 28-day all-cause mortality
title_fullStr Looking beyond 28-day all-cause mortality
title_full_unstemmed Looking beyond 28-day all-cause mortality
title_short Looking beyond 28-day all-cause mortality
title_sort looking beyond 28-day all-cause mortality
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137308/
https://www.ncbi.nlm.nih.gov/pubmed/12225601
work_keys_str_mv AT rubenfeldgordon lookingbeyond28dayallcausemortality